Evan Seigerman
Stock Analyst at BMO Capital
(4.13)
# 470
Out of 5,147 analysts
154
Total ratings
55.88%
Success rate
12.25%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $147 → $140 | $132.25 | +5.86% | 16 | Feb 12, 2026 | |
| BIIB Biogen | Maintains: Market Perform | $165 → $196 | $191.82 | +2.18% | 28 | Feb 9, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $35 → $54 | $42.12 | +28.21% | 3 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,100 → $1,200 | $1,051.99 | +14.07% | 10 | Dec 4, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $120 → $130 | $148.95 | -12.72% | 18 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $496.83 | +6.68% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $101.27 | -40.75% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $66.62 | +80.13% | 6 | May 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $62.37 | -2.20% | 11 | Nov 12, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $62.98 | -36.49% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $40 | $7.65 | +422.88% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $781.67 | +0.81% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $5.91 | -57.70% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $388.16 | -37.40% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $5.25 | +128.57% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $27.65 | +117.00% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.99 | +1,407.54% | 3 | May 12, 2020 |
Neurocrine Biosciences
Feb 12, 2026
Maintains: Market Perform
Price Target: $147 → $140
Current: $132.25
Upside: +5.86%
Biogen
Feb 9, 2026
Maintains: Market Perform
Price Target: $165 → $196
Current: $191.82
Upside: +2.18%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $35 → $54
Current: $42.12
Upside: +28.21%
Eli Lilly and Company
Dec 4, 2025
Maintains: Outperform
Price Target: $1,100 → $1,200
Current: $1,051.99
Upside: +14.07%
Gilead Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $120 → $130
Current: $148.95
Upside: -12.72%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $496.83
Upside: +6.68%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $101.27
Upside: -40.75%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $66.62
Upside: +80.13%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $62.37
Upside: -2.20%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $62.98
Upside: -36.49%
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $7.65
Upside: +422.88%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $781.67
Upside: +0.81%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $5.91
Upside: -57.70%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $388.16
Upside: -37.40%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $5.25
Upside: +128.57%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $27.65
Upside: +117.00%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.99
Upside: +1,407.54%